Templates for CDC Recommended Childhood Vaccines:

1. HepB (Hepatitis B)

This vaccine is contraindicated for name because it contains Lactate dehydrogenase-elevating virus (LDV) which is a mouse arterivirus pathogenic infection of neurons in the central nervous system. *The vaccine also contains Envelope E protein - 75 amino acids long, the envelope (E) protein is the smallest of the four structural proteins that make up the SARS-CoV-2 viral particle and is essential for the virus to infect cells. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

Safety Datasheet: ENGERIX-B PRESERVATIVE FREE = * HEPATITIS B SURFACE ANTIGEN <u>https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_SMKLPH_ENGERIXB_SYR_TIP_LOK_10MCG0.p</u> <u>df</u>

Vaccine – Hepatitis B (Recombinant DNA) Vaccine (Absorbed)

Composition/information on ingredients: Disodium Hydrogen Phosphate <u>https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_SMKLPH_ENGERIXB_SYR_TIP_LOK_10MCG0.p</u> <u>df</u>

*Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282743/

2. RV* Rotavirus

This vaccine is contraindicated for name because it increased risk of **intussusception** in vaccinated infants. **Intussusception** is a medical emergency that needs care right away. It is the most common abdominal emergency in children under 2 years old. An associated protein coding gene (ingredient) is CRAT (Carnitine O-acetyltransferase). Diseases Associations are: Acute diabetes complication and Ischemia; and diseases associated with CRAT include **Neurodegeneration With Brain Iron Accumulation 8 and Neurodegeneration With Brain Iron Accumulation 8 and Neurodegeneration With Brain Iron Accumulation** (NBIA). NBIA are neurologic disorders, causing include; muscular spasms, twisting, and repetitive movements, spasticity, parkinsonism (slurred or slow speech, stiffness of the muscles, slow movement, and visible tremors), inability to coordinate movements (ataxia), neuropsychiatric abnormalities (confusion, disorientation, seizures, stupor, dementia), and eye problems, such as optic atrophy or retinal degeneration. Cerebellar atrophy is common in many cases. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

https://www.sciencedirect.com/science/article/abs/pii/S0264410X21012822

Supporting studies/evidence:

What Is Intussusception?

https://kidshealth.org/en/parents/intussusception.html https://www.mayoclinic.org/diseases-conditions/intussusception/symptoms-causes/syc-20351452

Neurodegeneration with Brain Iron Accumulation

https://rarediseases.info.nih.gov/diseases/11899/neurodegeneration-with-brain-iron-accumulation

3. DTaP Diphtheria, Pertussis, & Tetanus - BOOSTRIX (FDA recommended)

This vaccine is contraindicated for name because it contains **Recombinant Exotoxin A of Pseudomonas aeruginosa**. **Exotoxin A** is a potent cytotoxin and is known to be lethal. Exotoxin A causes disease by inhibition of protein synthesis, direct cytopathic effects, and interference with cellular immune functions of the host/ child. BOOSTRIX also is linked to the protein **Mucin-1 (human)**, which contributes to cellular processes and dysregulation, and can facilitate in distinct human diseases. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence: The role of exotoxin A in pseudomonas disease and immunity https://pubmed.ncbi.nlm.nih.gov/6419320/

Mucin-1 (human)

Mucin 1 - Protein-Disease Associations - https://pubchem.ncbi.nlm.nih.gov/protein/P15941 - section=Diseases-and-Phenotypes

Diphtheria toxoids

https://www.cdc.gov/vaccines/pubs/pinkbook/dip.html

4. Hib* Haemophilus influenzae type b

PedvaxHIB (PRP-OMP, Merck) -

Synonym: Neisseria Meningitidis Serogroup B (B-11 Strain) Outer Membrane Protein Complex Thiol Modified For Conjugation

This vaccine is contraindicated for name. because it contains the chemical **Atropine**, which is registered as a hazardous substances, and an environmental contaminant. Atropine in toxic amounts leads to drowsiness, stupor, convulsions, & coma, and death. Symptoms of atropine toxicity include: dryness of the mouth; flushed, hot, & dry skin; dilated & nonreactive pupils; tachycardia; hallucinations; & restlessness. Seizures without prior evidence of hallucinations or delirium have followed the use of atropine in children. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

haemophilus b conjugate vaccine (meningococcal protein conjugate)

https://www.drugs.com/pro/pedvaxhib.html

Atropine -

Atropine has been used as a premedication in obstetric anesthesia, as a test of fetoplacental insufficiency, & in the diagnosis of fetal asphyxia (atropine given to the mother produces changes in the fetal heart rate: first bradycardia, then tachycardia). There is evidence of rapid placental transfer of atropine. https://pubchem.ncbi.nlm.nih.gov/source/hsdb/2199

Atropine Data sheet -

https://pubchem.ncbi.nlm.nih.gov/compound/Atropine - section=GHS-Classification

Neisseria Meningitidis Serogroup B (B-11 Strain) Outer Membrane Protein Complex Thiol Modified For Conjugation

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/MC95ZF3C5A https://gsrs.ncats.nih.gov/ginas/app/beta/substances/46KSF1PRP7

5. PCV13, PCV15 (Pneumococcal disease)

Name: Vaxneuvance (Merck) Pneumococcal 15-valent - suspension for injection in pre-filled syringe

This vaccine is contraindicated for name because it contains **Amlodipine** (Norvasc). Amlodipine is an antihypertensive agent, and a vasodilator agent; which can cause a decrease in blood pressure. *GHS Hazard Statements - Toxic if swallowed. Danger Acute toxicity, oral corrosive, and an environmental contaminant. Causes serious eye damage. Causes damage to organs through prolonged or repeated exposure. *Warning: Specific target organ toxicity, repeated exposure. Very toxic to aquatic life with long lasting effects. This presents a clear medical danger to name because this toxin would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence

Amlodipine

https://pubchem.ncbi.nlm.nih.gov/compound/amlodipine

Norvasc

https://www.mayoclinic.org/drugs-supplements/amlodipine-oral-route/description/drg-20061784

Pneumococcal Polysaccharide Vaccine [Chemical/Ingredient] (Code N0000179488)

https://nciterms.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NDFRT&version=February2018&code=N0 000179488&ns=NDFRT&type=all&key=null&b=1&n=0&vse=null

6. IPV - Poliovirus Vaccine, inactivated

This vaccine is contraindicated for name because it contains **Neomycin**, a chemical compound that can produce neurotoxicity, ototoxicity and/or nephrotoxicity. Neomycin is associated with delayed-onset irreversible deafness, renal failure and death due to neuromuscular blockade (regardless of the status of renal function). GHS Hazard Statements: Harmful if swallowed: Acute toxicity, oral. May cause a serious allergic skin reaction May cause allergy or asthma symptoms or breathing difficulties if inhaled. Inactivated poliovirus vaccine administration has been associated with Guillain-Barre Syndrome. *Neomycin is used in veterinary medicine as a bactericidal drug. This presents a clear medical danger to name because this toxin would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

Neomycin https://pubchem.ncbi.nlm.nih.gov/compound/neomycin

*Neomycin - Necrosis - The death of cells in an organ or tissue due to disease, injury or failure of the blood supply. Associated Disorders and Diseases. DNA Degradation, Necrotic - The random catabolism of DNA accompanying the irreversible damage to tissue which leads to the pathological death of one or more cells. https://pubchem.ncbi.nlm.nih.gov/compound/neomycin - section=Associated-Disorders-and-Diseases

7. COVID-19** Coronavirus disease 2019

This recombinant nanoparticle vaccine is contraindicated for name because it contains the full-length spike glycoprotein of the prototype strain plus *Matrix-M adjuvant. Matrix-M adjuvant induces early activation of innate immune cells at the injection site and in the draining lymph nodes. It is unsafe when used in larger amounts as medicine. The Matrix-M adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria Molina tree, combined with cholesterol and phospholipids to form 40-nm open cage-like nanoparticles. Quillaia contains high amounts of tannins which can cause stomach problems, as well as kidney and liver damage. Quillaia also contains chemicals called oxalates, which can cause kidney stones. Additional serious adverse events with this vaccine: cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Novavax COVID-19 Vaccine, Adjuvanted. *NVX-CoV2373 in the United States has received Emergency Use Authorization, it is not FDA approved This presents a clear medical danger to name because this toxins, and the additional adverse health concerns would be exacerbated by introduction of this substance to his/her body.

FDA Briefing Document Novavax COVID-19 Vaccine

https://www.fda.gov/media/158912/download

Supporting studies/evidence

Matrix-M[™] Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0041451

Additional information on Novavax

*The Novavax COVID-19 Vaccine, Adjuvanted is a suspension for intramuscular injection.

Product label Generic name: nvx-cov2373 Dosage form: injection, suspension Drug class: Viral vaccines Vaccination providers enrolled in the federal COVID-19 Vaccination Program must report all vaccine administration errors, all serious adverse events, cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Novavax COVID-19 Vaccine, Adjuvanted.

See "MANDATORY REQUIREMENTS FOR THE NOVAVAX COVID-19 VACCINE, ADJUVANTED ADMINISTRATION UNDER EMERGENCY USE AUTHORIZATION" for reporting requirements. https://www.drugs.com/pro/covid-19-vaccine-novavax.html

8. Flu† Influenza

This vaccine is contraindicated for name because it can trigger severe allergic reactions such as asthma and precaution is advised with use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged \geq 5 years because of concerns for wheezing events. Reactions include, in addition to asthma (e.g., anaphylaxis) egg, (egg protein) neuralgia, paresthesia,

convulsions (including febrile seizures), encephalopathy, neuritis or neuropathy, transverse myelitis, Guillain-Barre Syndrome, dizziness, hypoesthesia, tremor, facial or cranial nerve paralysis, encephalopathy, limb paralysis, confusion, paralysis (including Bell's Palsy), exacerbation of symptoms of mitochondrial encephalomyopathy (Leigh syndrome), meningitis, eosinophilic meningitis, vaccine associated encephalitis. This presents a clear medical danger to name because these potentially dangerous medical concern would be exacerbated by introduction of this vaccine to his/her body.

Supporting studies/evidence:

FLUMIST® QUADRIVALENT safely and effectively. See full prescribing information for FLUMIST® https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2022-2023-season

Afluria Quadrivalent 2022-2023 (injection)

https://www.drugs.com/mtm/afluria-quadrivalent-2022-2023-injection.html https://www.drugs.com/sfx/afluria-quadrivalent-side-effects.html

9. MMR Measles, Mumps, & Rubella

This vaccine is contraindicated for name, and certain individuals including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to *Neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness. Adverse concerns/ reactions are seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; and thrombocytopenia. These medical concerns and reactions presents a clear medical danger to name due to ingredients that would be exacerbated by introduction of these substance to his/her body.

Supporting studies/evidence:

MMR Vaccine - Priorix

https://www.chop.edu/news/news-views-what-should-i-know-about-new-mmr-vaccine-priorix

Priorix

https://ca.gsk.com/media/6254/priorix.pdf

*Neomycin

https://pubchem.ncbi.nlm.nih.gov/compound/neomycin

*Neomycin - Necrosis - The death of cells in an organ or tissue due to disease, injury or failure of the blood supply. Associated Disorders and Diseases. DNA Degradation, Necrotic - The random catabolism of DNA accompanying the irreversible damage to tissue which leads to the pathological death of one or more cells. https://pubchem.ncbi.nlm.nih.gov/compound/neomycin - section=Associated-Disorders-and-Diseases

10. Varicella (Chickenpox)

This vaccine is contraindicated for name because it contains the chemical compound, **ALB - albumin (human).** Implicated in several diseases, including blood protein disease; hepatobiliary system cancer (multiple); hyperthyroxinemia; middle cerebral artery infarction; and psoriasis. Biomarker of several diseases, including carcinoma (multiple); heart disease (multiple); hematologic cancer (multiple); liver disease (multiple); and lung disease (multiple). This presents a clear medical danger to name because this toxin would be exacerbated by introduction of this substance to his/her body. *Note: This gene has been reviewed for its involvement in coronavirus biology, and is relevant for COVID-19 prognosis.

Supporting Studies/evidence: ALB - albumin (human).

https://pubchem.ncbi.nlm.nih.gov/gene/213

Albumin (human) https://www.drugs.com/mtm/albumin-human.html

11. HepA[‡] Hepatitis A

This vaccine is contraindicated for name because it contains **Aluminum**. Aluminum negatively effects the central nervous system and bones. Aluminum binds to dietary phosphorus and impairs gastrointestinal absorption of aluminum. The decreased phosphate body burden results in osteomalacia and rickets. Aluminum neurotoxicity is believed to involve different mechanisms. Aluminum may induce neurobehavioral effects by affecting permeability of the blood-brain barrier, cholinergic activity, signal transduction pathways. It has been suggested that aluminum's interaction with estrogen receptors increases the expression of estrogen-related genes and thereby contributes to the progression of breast cancer. This presents a clear medical danger to name because this chemical compound is toxic, and would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

Havrix[®] (Hepatitis A Vaccine) injectable suspension, for intramuscular use <u>https://ca.gsk.com/media/6243/havrix.pdf</u>

Al_2O_3 nanoparticles induce mitochondria-mediated cell death and upregulate the expression of signaling genes in human mesenchymal stem cells

https://pubmed.ncbi.nlm.nih.gov/23132795/

12. Tdap: ≥7 yrs.

This vaccine is contraindicated for name because it contains **Neomycin**, a chemical compound that can produce neurotoxicity, ototoxicity and/or nephrotoxicity. Severe allergic reaction (e.g., anaphylaxis) and progressive neurologic disorders, include - hypersensitivity and encephalopathy. Neomycin is associated with delayed-onset irreversible deafness, renal failure and death due to neuromuscular blockade (regardless of the status of renal function). Neomycin is used in veterinary medicine as a bactericidal drug. GHS Hazard Statements: Harmful if swallowed - Warning Acute toxicity, oral. May cause an allergic skin reaction May cause allergy or asthma symptoms or breathing difficulties if inhaled. This presents a clear medical danger to name because this toxin would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

Neomycin https://pubchem.ncbi.nlm.nih.gov/compound/neomycin

Neomycin

https://pubchem.ncbi.nlm.nih.gov/compound/neomycin

*Neomycin - Necrosis - The death of cells in an organ or tissue due to disease, injury or failure of the blood supply. Associated Disorders and Diseases. DNA Degradation, Necrotic - The random catabolism of DNA accompanying the irreversible damage to tissue which leads to the pathological death of one or more cells. https://pubchem.ncbi.nlm.nih.gov/compound/neomycin - section=Associated-Disorders-and-Diseases

13 (HPV) Human Papillomavirus

This vaccine is contraindicated for name because it contains serious health concerns for anyone with allergic food (yeast), Adverse side effects associated HPV vaccine are: difficulty breathing, wheezing (bronchospasm), hives, rash, vomiting, swollen glands (neck, armpit, or groin) joint pain unusual tiredness, weakness, or confusion, chills, generally feeling unwell, leg pain, shortness of breath, chest pain, aching muscles, muscle weakness, seizure, bleeding or bruising more easily than normal, skin infection. *There are 85 Papillomavirus type strains (including non -human strains) linked to this CDC Recommended Vaccine. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

Patient Information about GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) https://www.fda.gov/media/90070/download?attachment

***Patent Summary: Vaccine against HPV – 85 linked Papillomavirus strains** https://pubchem.ncbi.nlm.nih.gov/patent/EP-2318042-B1 - section=Linked-Proteins

14. Meningococcal (MenACWY-D: ≥9 mos, MenACWY-CRM: ≥2 mos, MenACWY-TT: ≥2years)

This vaccine is contraindicated for name because it contains the chemical compound, Diphtheria Toxoid. As an ingredient, it is a carrier protein for polysaccharides and haptens to make them immunogenic. The toxicity of Diphtheria Toxoid (CRM197) can cause damage to yeast cells and some mammalian cell lines. Haptens are small molecules that elicit an immune response when attached to a large carrier such as a protein; and they activate responses involving inflammatory cytokines. *Examples of post market side adverse effects, associated with this vaccine include (not limited too) - Blood and Lymphatic System Disorders, Lymphadenopathy, Immune System Disorders, Hypersensitivity reactions such as anaphylaxis/anaphylactic reaction, wheezing, difficulty breathing, upper airway swelling, urticaria, erythema, pruritus, and hypotension. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

Supporting studies/evidence:

LABEL: MENACTRA-

Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen, Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen, Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen, and Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen, solution

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d8781ff-9366-462c-8161-6e958f44fcb4&audience=consumer - S11

Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine https://www.vaccineshoppe.com/assets/pdf/vsh/pi/menactrapi.pdf

15. Meningococcal serogroup B vaccination

This vaccine is contraindicated for name because it contains an ingredient, Fc gamma receptor and transporter (FCGRT). This gene encodes a receptor that binds immunoglobulin G; and also binds immunoglobulin G to protect the antibody from degradation. Due to alternative splicing caused by interaction with various ingredients in the vaccine, multiple transcript variant can occur, and trigger autoimmune reactions. Disease associated with FCGRT is Myasthenia gravis. Myasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in weakness of the skeletal muscles. Myasthenia gravis affects the voluntary muscles of the body, especially those that control the eyes, mouth, throat and limbs. The disease can strike anyone at any age. A myasthenia gravis crisis can involve difficulty in swallowing or breathing. The cause of myasthenia gravis is unknown and there is no cure. *The encoded protein transfers immunoglobulin G antibodies from mother to fetus across the placenta. This presents a clear medical danger to name because these toxins would be exacerbated by introduction of this substance to his/her body.

Meningococcal group B vaccine Side Effects

https://www.drugs.com/sfx/meningococcal-group-b-vaccine-side-effects.html

Myasthenia Gravis

https://www.hopkinsmedicine.org/health/conditions-and-diseases/myasthenia-gravis

16. (PPSV23) pneumococcal polysaccharides vaccine (PPSV), 23-valent

This vaccine is contraindicated for name because it contains such harsh ingredients, and known toxins that trigger life threatening allergic reactions, and onset infections. A few examples of these life-threatening reactions are: Febrile convulsion, which are seizures or convulsions that occur in young children. Symptoms may include: loss of consciousness or passing out; uncontrollable shaking; eye rolling; rigid (stiff) limbs. Myocardial infarction (commonly called a heart attack) is an extremely dangerous condition that happens because of a lack of blood flow to your heart muscle; often resulting in death. Injection Cellulitis; Cellulitis is a potentially serious bacterial skin infection. The affected skin is swollen and inflamed and is typically painful and warm to the touch. Cellulitis is usually a superficial infection of the skin; if severe or if left untreated, it can spread into the lymph nodes and bloodstream and rapidly become life-threatening. These potential reactions presents a clear medical danger to name because these reactions would be exacerbated by introduction of this substance to his/her body.

PNEUMOVAX 23 is indicated to help prevent pneumococcal disease caused by 23 serotypes https://www.merckvaccines.com/pneumovax23/

Pneumovax 23 Side Effects

Generic name: pneumococcal 23-polyvalent vaccine

https://www.drugs.com/sfx/pneumovax-23-side-effects.html

Febrile Seizures

https://www.ninds.nih.gov/health-information/disorders/febrile-seizures

Heart Attack (Myocardial Infarction)

https://my.clevelandclinic.org/health/diseases/16818-heart-attack-myocardial-infarction

Cellulitis

https://www.mayoclinic.org/diseases-conditions/cellulitis/symptoms-causes/syc-20370762

17. (DEN4CYD: 9-16 yrs.)

1. This vaccine is contraindicated for name because it has extreme adverse side effects, causing damaging health concerns. Some of them were: bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage; Shock and hypotension with tachycardia, weak pulse and poor perfusion; Bleeding requiring blood transfusion; Encephalopathy i.e., unconsciousness or poor conscious state; poor conscious state or unconsciousness; Myocarditis, and pericarditis.

2. Sanofi Pasteur licensed the first dengue vaccine (Dengvaxia®) in Mexico in 2015, and more than 20 countries, thereafter, based on the safety and efficacy demonstrated in two phase III trials and a single season of disease surveillance. Unfortunately, the optimism that a dengue vaccine was finally available quickly became disappointment when a safety signal was observed in vaccine recipients who were dengue non-immune at the time of vaccine administration 44.45. In the third year of the phase III clinical trial, the youngest, non-immune vaccine recipients experienced increased rates of hospitalized and severe dengue compared to their unvaccinated peers 46. These potential reactions presents a clear medical danger to name because these toxins and/or reactions would be exacerbated by introduction of this substance to his/her body.

1. Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

https://classic.clinicaltrials.gov/ct2/show/NCT01374516

2. Is new dengue vaccine efficacy data a relief or cause for concern?

https://www.nature.com/articles/s41541-023-00658-2

*Additional Information:

HepA Hepatitis A Vaccines - Associated Disorders and Diseases

Autism Spectrum Disorder Multiple Sclerosis, Chronic Progressive Bone Diseases, Metabolic Cardiovascular Diseases Brain Diseases Anemia Eye Diseases Memory Disorders **Cognition Disorders** Granuloma Heart Defects, Congenital Epilepsy, Tonic-Clonic Fragile X Syndrome Inflammation Lung Diseases Osteomalacia Lymphadenitis Nerve Degeneration Parkinson Disease

Neoplasms Osteoporosis **Bronchial Hyperreactivity** Multiple Sclerosis, Relapsing-Remitting Neurodegenerative Diseases Chronic Kidney Disease-Mineral and Bone Disorder Chemical and Drug Induced Liver Injury Poisoning **Diabetes Complications Dyslipidemias Respiratory Tract Diseases** Neurotoxicity Syndromes Weight Loss Heavy Metal Poisoning Patent - Vaccine against HPV - GLAXOSMITHKLINE BIOLOG SA (BE) (HPV) Human Papillomavirus Stains - Presented as linked Proteins in Vaccine P50805 Major capsid protein L1 (Xipapillomavirus 1) P08341 Major capsid protein L1 (Bos taurus papillomavirus 4) P50807 Major capsid protein L1 (Bos taurus papillomavirus 6) P03104 Major capsid protein L1 (Deltapapillomavirus 2) P11326 Major capsid protein L1 (Deltapapillomavirus 1) P22163 Major capsid protein L1 (Alpha papillomavirus 12) Q02273 Major capsid protein L1 (human papillomavirus 13) <u>Q02274</u> Major capsid protein L1 (Pygmy chimpanzee papillomavirus type 1) P06456 Major capsid protein L1 (Chaffinch papillomavirus) P06417 Major capsid protein L1 (Human papillomavirus type 8) P04012 Major capsid protein L1 (human papillomavirus 11) P03099 Major capsid protein L1 (Human papillomavirus type 1a) P25486 Major capsid protein L1 (Human papillomavirus type 2a) P17388 Major capsid protein L1 (human papillomavirus 31) P06416 Major capsid protein L1 (human papillomavirus 33) P27232 Major capsid protein L1 (human papillomavirus 35) P24838 Major capsid protein L1 (human papillomavirus 39) P27557 Major capsid protein L1 (Human papillomavirus type 41) P27233 Major capsid protein L1 (human papillomavirus 42) P50815 Major capsid protein L1 (human papillomavirus 43) P50816 Major capsid protein L1 (human papillomavirus 44) P36741 Major capsid protein L1 (human papillomavirus 45) P22424 Major capsid protein L1 (human papillomavirus 47) P26536 Major capsid protein L1 (human papillomavirus 51) <u>P36743</u> Major capsid protein L1 (human papillomavirus 56) P26535 Major capsid protein L1 (human papillomavirus 58) P26537 Major capsid protein L1 (Human papillomavirus type 5b) P69899 Major capsid protein L1 (Human papillomavirus type 6b) P27964 Major capsid protein L1 (Human papillomavirus type me180) P36733 Major capsid protein L1 (human papillomavirus 12) P36734 Major capsid protein L1 (human papillomavirus 14) 005137 Major capsid protein L1 (Human papillomavirus 15) 002514 Major capsid protein L1 (Human papillomavirus 17) Q02050 Major capsid protein L1 (Human papillomavirus 19) Q02051 Major capsid protein L1 (human papillomavirus 25) Q02515 Major capsid protein L1 (human papillomavirus 30) P36731 Major capsid protein L1 (Human papillomavirus 3) P36740 Major capsid protein L1 (human papillomavirus 40) P36742 Major capsid protein L1 (Human papillomavirus type 49)

Q07860 Major capsid protein L1 (Human papillomavirus 4) **O**05138 Major capsid protein L1 (human papillomavirus 52) Q05136 Major capsid protein L1 (Human papillomavirus type 7) Q024<u>80</u> Major capsid protein L1 (Human papillomavirus 9) Q07861 Major capsid protein L1 (Human papillomavirus type 63) **O**07874 Major capsid protein L1 (Human papillomavirus 65) P50786 Major capsid protein L1 (human papillomavirus 20) P50787 Major capsid protein L1 (human papillomavirus 21) P03102 Major capsid protein L1 (Papillomavirus sylvilagi (STRAIN KANSAS)) P50791 Major capsid protein L1 (Human papillomavirus 28) P50792 Major capsid protein L1 (Human papillomavirus 29) P50820 Major capsid protein L1 (Human papillomavirus type 55) P50822 Major capsid protein L1 (Human papillomavirus type 61) P50824 Major capsid protein L1 (Human papillomavirus type 64) Q80961 Major capsid protein L1 (human papillomavirus 66) P50825 Major capsid protein L1 (human papillomavirus 67) P50826 Major capsid protein L1 (human papillomavirus 69) P69898 Major capsid protein L1 (Human papillomavirus type 6a) P50788 Major capsid protein L1 (Human papillomavirus 22) P50789 Major capsid protein L1 (Human papillomavirus 23) P50790 Major capsid protein L1 (human papillomavirus 24) P50812 Major capsid protein L1 (human papillomavirus 36) P50813 Major capsid protein L1 (Human papillomavirus 37) P50814 Major capsid protein L1 (Human papillomavirus 38) P50793 Major capsid protein L1 (Human papillomavirus type 70) P50806 Major capsid protein L1 (Epsilon papillomavirus 1) P50817 Major capsid protein L1 (Human papillomavirus type 48) P50818 Major capsid protein L1 (Human papillomavirus type 50) P50821 Major capsid protein L1 (Human papillomavirus type 60) P54669 Major capsid protein L1 (human papillomavirus 68) **Q9IR52** Major capsid protein L1 (human papillomavirus 82) P36736 Major capsid protein L1 (human papillomavirus 27) P22162 Major capsid protein L1 (human papillomavirus 57) P36732 Major capsid protein L1 (Human papillomavirus type 10) P03101 Major capsid protein L1 (Human papillomavirus type 16) P06794 Major capsid protein L1 (Human papillomavirus type 18) P36735 Major capsid protein L1 (Human papillomavirus type 26) P36737 Major capsid protein L1 (Human papillomavirus type 32) P36738 Major capsid protein L1 (Human papillomavirus type 34) O05113 Major capsid protein L1 (Human papillomavirus type 53) P06917 Major capsid protein L1 (Human papillomavirus 5) P50823 Major capsid protein L1 (human papillomavirus 62) P03103 Major capsid protein L1 (Deltapapillomavirus 4) Q89828 Major capsid protein L1 (Canine oral papillomavirus (strain Y62)) P50819 Major capsid protein L1 (Human papillomavirus type 54) P06458 Major capsid protein L1 (Bos taurus papillomavirus 2)